~ , .
| ,
|
| , ,
|
| , ,
~ .
| -
| -
|
|
|
~ - .
|
|
|
|
| ,
~ 3 .
|
|
|
|
|
~ .
|
|
|
|
|
~ , , .
|
|
|
| in vitro
|
~ , .
|
|
|
| in vitro
|
~ , , , ,
|
|
|
| in vitro
|
~ 1,2; 4,5 6,8 .
| in vitro
|
|
|
|
|
|
~ , , (D, ) (S, /) pH.
|
|
|
|
|
~ .
| ,
|
|
|
|
~ , .
|
|
|
|
|
~ ....
| (ICH)
| (GMP)
| (GLP)
| ()
| (GCP)
~ :..., .
|
|
|
|
|
~, ....
|
|
|
| ,
| ,
~ , , ... .
| 60
| 30
| 15
| 5
| 20
~ , , ... .
| 30
| 60
| 15
| 5
| 20
~ - .
|
|
|
|
| ,
~ - .
|
|
|
|
| ,
~ .
|
|
|
|
| , ,
~ .
|
|
|
|
|
~ , 45 .
|
|
|
|
|
|
|
~ . () .
|
|
|
|
|
~ 75% 115% .
|45
|15
|60
|30
|1
~ 1 (/3) .
|10-3
|0,01
|0,1
|10-5
|0,001
~ 2 (/3) .
|0,01
|10-3
|0,1
|10-5
|0,001
~ .
|
|
|
|
|
~ , , ... .
|
|
|
|
|
~... , , .
|
|
|,
| -
|
~... .
|
|
|,
| -
|
~ : , , 100-1050C 3 , ....
|
|
|
|
|
~ : 10,0 , 1 , , , , , , 100 ....
|
|
|
|
|
~ 2 0.01 ....
|
|
|
|
|
~ ....
|
|
|
|
|
~ ....
|
|
|
|
|
~ ....
|
|
|
|
|
~ , , .
|
|
|
|
|
|
|
~ 2- .
|0,05%
|5%
|1,05%
|3%
|10%
~ 2- .
|0,05%
|5%
|1%
|3,05%
|10%
~ : , , , , 0,1 ....
|
|
|
|
|
~ , - , 0,1 ....
| 2 3
| 15 30
| 45 60
| 1
| 2
~ , - , 6,8 ....
| 60
| 15 30
| 10 15
| 15
| 30
~ , , , , ....
| 60
| 15 30
| 10 15
| 15
| 30
~ , , , , 0,1 ....
| 60
| 15 30
| 10 15
| 15
| 30
~ , ....
| 15
| 15 30
| 2 3
| 15
| 30
~ ....
|
| -
|
|
|
~ ....
|
| -
|
|
| -
~
.
|
|
|
|
|
~ , , , , .
|
|
|
|
|
|
|
~ .
|
|
| ,
|
|
~ .
|
|
|,
|
|
~...- , .
|
|
|
|
|
~ : , , . , , 5 ....
|
|
|
|
|
~ .
|
|
|
|
|
~ .
|
|
|
|
|
~ .
|
|
|
|
|
~ .
|
|
|
|
|
~ , .
|
|
|
|
|
~ - , .
|
|
|
|
|
~ - , .
|
|
|
|
|
~ , .
|
|0,1
|
|
|
~ .
|
|
|
|
|
~ .
|
|
|
|
|
~. - , , , , , .
|International conference of harmonization (ICH)
|Food and Drug Administration (FDA)
|Good Participation Practice (GPP)
|European Medicines Agency (EMEA)
|Good Manufacturing Practice (GMP)
~ ICH .
|Q1
|M4
|E5
|Q10
|Q9
~ ICH .
|Q3A(R2)
|Q2(R1)
|Q3C(R3)
|Q3B(R2)
|Q1A(R2)
~ ICH Q2(R1) .
|
|
|
|GMP
| ,
~ ICH .
|
|
|E2E
|E2B(R3)
|E2A
|E2D
|E2C(R1)
~ , , .
|
|
|
| GLP
| GVP
~ ICH .
|Q4
|Q2
|Q8
|Q9
|Q1
~ ICH :
|, ,
|,
|, ,
|,
|
~ ICH :
|World Health Organization (WHO)
|The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
|European Union (EU)
| Pharmaceutical Research and Manufacturers of America (PhRMA)
|Food and Drug Administration, USA (FDA)
~ICH .
| (ICH Parties), (Observers) IFPMA
| (Observers), IFPMA
| (ICH Parties) (Observers)
| -,
| , EFTA
~ ICH .
|Q8
|M4
|E5
|Q9
|9
~ ICH GCP .
|E6(R1)
|E2B(R3)
|E2A
|E2D
|E2C(R1)
~ ICH S2B .
|
|
|
|GMP
|
~ ICH .
|S1A
|1B
|E2A
|S2B
|Q3A
~ ICH M1 .
|
|
|
| ()
|
~- .
|
|
|
|
|
~ - , , () ,
|
|
| ()
|
|
~ , .
| ,
|
|
|
| ,
~ , , .
|
|
|
| ()
|
~ , , , .
|
|
|
| ()
|
~ .
| ()
|
| ()
| ()
| ()
~ .
|
|
|
|
|
~ ....
|
|
|
|
|
~ , , , , 3 .
|,
|,
| ,
|
|
~ ... , () 5 25.
|
|
|
|
|
~ 2 8 ....
|
|
|
|
|
~ -15 ....
|
|
|
|
|
~ 8 15 ....
|
|
|
|
|
~ 15 25 ....
|
|
|
|
|
~ ... .
|
|
|
|
|
~ ... .
|
|
|
|
|
~ , ....
|6
|1
|2
|2
| 2
~ ....
|,
| ,
| ,
| ,
|,
~ III ... , 15% .
|
|
|
|
|
~... .
|
|
|
| ()
|
~... .
|
|
|
| ()
|
~ .
|
|
|
|
~ .
|
| ,
| ,
| ,
|
~ - .
| ,
|
| , ,
|
| ,
~ (r) .
|r ≥ 0,99
| r < 0,95
|r = 0,95
| r > 1
|r < 3,2
~ .
|
|
|
|
|
~ .
|
|
|
|
|
~ - .
| (r)
|
| b
| a
|
~ .
|
|
|
|
| b
~ .
|c ,
| ,
|
| ,
| ,
~ .
|
|
|
|
|
~ .
| (Good Laboratory Practice, GLP)
| (Good Clinical Practice, GCP)
| (Good Distribution Practice, GDP)
| () (Good Pharmacy Practice, GPP)
| (Good Manufacturing Practice, GMP)
~ .
| (Good Clinical Practice, GCP)
| (Good Laboratory Practice, GLP)
| (Good Distribution Practice, GDP)
| () (Good Pharmacy Practice, GPP)
| (Good Manufacturing Practice, GMP)
~ - , .
|
|
|
|
|-
~ .
|
| GMP
|
20%
|
|
20%
~ GMP .
| ,
|
|
|
|
~ GMP .
| , ,
|,
| ,
|
|
~ GLP .
|
|
|
|
|
~ - .
|
|
|
|
|
~ - .
|
|
|
|
|
~ , .
|
|
|
|
|
~: , .
|
|
|
|
|
~: , () .
|
|
|
|
|
~: .
|
|
|
|
|
~ .
|,
|
|
|
|
~ .
|
|
|
|
|
~ , .
|
|
|
|
|
~ .
|
|
|
|
|
~ .
| ( ) (/)
| 1
| -
| , ml .
| - 1 .
~ .
| / 0
|
|
|
|
~ .
|
|
|
|
|
~ .
|
|
|
|
|
~ - .
|,
|
|
|
|
~ - .
|, ()
|
|
|
|
~ .
| ,
|
|,
|
| .
~ .
|, ,
| , ()
|
|
|
~ .
|
|-
|
|
|
~ .
|
| -
|
|
|
~ .
| ,
|
|
| ѻ
| ѻ
~ .
|
|
|
|
|
~ .
|
|
|
|
|
~ - .
|
|
|
|
|
~ .
|-
|
|
|
|
~ .
|
| ,
|
|
|
~ - .
|